Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-low Breast Cancer”

188 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 188 results

Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Early research (Phase 1)Study completedNCT00821054
What this trial is testing

Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 24
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Not applicableLooking for participantsNCT07630402
What this trial is testing

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
University of Rochester 20
Not applicableNot Yet RecruitingNCT07130344
What this trial is testing

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Who this might be right for
Metastatic Breast CancerHER 2 Low-expressing Breast Cancer
Centre Paul Strauss 262
Large-scale testing (Phase 3)UnknownNCT03507465
What this trial is testing

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Guangdong Provincial People's Hospital 290
Testing effectiveness (Phase 2)UnknownNCT02829008
What this trial is testing

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
Chinese Academy of Medical Sciences 120
Testing effectiveness (Phase 2)Looking for participantsNCT07276880
What this trial is testing

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)HER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center 32
Post-approval studies (Phase 4)UnknownNCT05861635
What this trial is testing

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Who this might be right for
Breast CancerNeoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 42
Testing effectiveness (Phase 2)UnknownNCT05806671
What this trial is testing

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Looking for participantsNCT06330064
What this trial is testing

Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Who this might be right for
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo 520
Large-scale testing (Phase 3)Not Yet RecruitingNCT07543536
What this trial is testing

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Who this might be right for
Advanced/Metastatic Breast CancerHER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Sun Yat-sen University 132
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Study completedNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 56
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Large-scale testing (Phase 3)Looking for participantsNCT06492616
What this trial is testing

Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 4,220
Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Not applicableEnrolling By InvitationNCT07132749
What this trial is testing

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

Who this might be right for
Patients With HER2-positive Advanced Breast Cancer Treated With T-DXdPatients With HER2-low Advanced Breast Cancer Treated With T-DXd
Yeon Hee Park 100
Load More Results